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1Introduction to DNP Practice Inquiry Project
Whitney R. Munroe
University of Kentucky
2Type 2 diabetes mellitus (DM) has reached epidemic proportions in the United States.
Current estimates predict that 29 million people, or approximately one in 11 persons, in the
country are currently diagnosed with type 2 DM and an additional 7 million remain undiagnosed,
which makes it the 7th leading cause of death nationwide (CDC, 2014). Additionally, 86 million
adults ≥ 20 years of age have pre-diabetes, which represents a significant increase in the
likelihood of progressing to type 2 DM within 10 years if risk factors are not controlled (CDC,
2014).
This disease has an enormous impact on the state of Kentucky, with an estimated 370,000
adults (10.7% of the population ≥18 years of age) having been diagnosed and an additional
233,000 with pre-diabetes (Kentucky Department for Public Health, 2010). This is higher than
the national average of 8.3% and places Kentucky at 7th in the nation for cases of diagnosed type
2 DM.  Currently, 40.1% of adults ages 40 to 74 have pre-diabetes, and type 2 DM is the 6th
leading cause of death in the state (Kentucky Diabetes Report Card, 2013).
In addition to helping patients reach glycemic targets, primary care providers are also
expected to identify and manage a variety of resulting complications, including diabetes-related
kidney disease. If identified early, the progression of this condition can be slowed, leading to
cost savings and increased patient quality of life.  This can be accomplished through screening as
recommended by the American Diabetes Association (ADA), which has been shown to be cost-
effective and beneficial to the care and treatment goals for patients with type 2 DM.
This Doctorate of Nursing Practice (DNP) Practice Inquiry Project investigates the
current screening rates for microalbuminuria, the earliest indicator of renal problems in patients
with type 2 DM. This project specifically addresses screening rates in the primary care setting.
3The first manuscript is a literature review, which focused on identification and treatment
strategies for diabetic kidney disease (DKD).  This review examined 10 articles that addressed
these areas. This literature review identified monitoring for and early identification of
microalbuminuria as the most important factor in preventing renal complications for patients
with type 2 DM, which led to the focus of the study.
The second manuscript reviewed a clinical practice guideline from the American
Diabetes Association (2015) regarding management of the patient diagnosed with diabetes.
While it addresses all areas of screening and management, special emphasis is placed on
recommendations for managing the renal complications of type 2 DM. Of these
recommendations, recommendation for screening included obtaining an annual urinary albumin
excretion level in all patients with type 2 DM, beginning at the time of diagnosis.  This led the
primary investigator (PI) to the question ‘What are the current rates of screening for urinary
albumin excretion levels in the primary care setting’?
The third manuscript serves as the report for a study completed in 2015 addressing
provider adherence to the ADA recommendation that all patients diagnosed with type 2 DM
receive annual screening for microalbuminuria, beginning at the time of diagnosis.  A
retrospective chart review was conducted in a primary care setting. Recommendations are also
provided regarding future research aimed to improve adherence to this recommendation.
4Prevention of Diabetes-Associated Renal Complications: A Literature Review
Whitney R.Munroe
University of Kentucky
5Abstract
Purpose: The purpose of this literature review is to review some of the preventive factors for
progression of microalbuminuria to overt diabetic kidney disease (DKD), as well as to explore
some of the current treatment strategies utilized to delay the onset of renal complications in
patients with type 2 diabetes.
Data Sources: The literature review was conducted using the CINAHL, PubMed, and Medline
Plus electronic databases.  Studies included were published between 1993 and 2013. Key words
included in the database search were “type 2 diabetes”, “microalbuminuria”, “diabetic kidney
disease”, “nephropathy”, and “renal complications”.
Conclusions: Many of the interventions utilized to treat diabetic kidney disease may delay, but
not reverse, the progression of this condition.  However, to reduce the progression to end stage
renal disease (ESRD), it is imperative that clinicians monitor for and provide adequate treatment
of this complication at the time of onset.
Implications for Practice: The most important consideration for preventing renal
complications associated with type 2 diabetes is the monitoring for and early identification of
microalbuminuria to prevent the progression to overt diabetic kidney disease (DKD).
Keywords: Type 2 diabetes mellitus, diabetic nephropathy, microalbuminuria, interventions
6Prevention of Diabetes –Associated Renal Complications: A Literature Review
Type 2 diabetes mellitus (DM) affects approximately 19.6 million Americans aged 18
and older, a statistic that has more than tripled since 1980 (Centers for Disease Control [CDC],
2013).  Type 2 DM accounts for 90 to 95% of all persons diagnosed with diabetes in the United
States (CDC, 2014).  The condition is diagnosed if an individual has a fasting blood glucose of ≥
126 mg/dl on two separate occasions, a random plasma glucose of ≥200 mg/dL accompanied by
classic symptoms of hyperglycemia (i.e., polyuria, polydipsia, weight loss, blurred vision,
fatigue), or an HbA1c level ≥6.5% (American Diabetes Association [ADA], 2015).
Healthy People 2020 identified increased quality of life for diabetic patients as a national
health care priority, including a reduction in the development of diabetes-related complications
(United States Department of Health and Human Services [DHHS], 2013). A specific objective
related to renal complications is Objective D-12 to ‘increase the proportion of persons with
diagnosed diabetes who obtain an annual urinary microalbumin measurement’.  In 2007, only
33.6 percent of Medicare beneficiaries with diabetes obtained a urinary microalbumin
measurement.  The goal of this objective is to increase the baseline rate by 10% to achieve at
least a 37% measurement rate (U.S. DHHS, 2013).  The 2015 Standards of Care from the
American Diabetes Association also contains multiple measures for detection and treatment of
diabetes-associated complications, including prevention, identification, and treatment of renal
complications (ADA, 2015).
Background
Type 2 DM is defined as a state of hyperglycemia resulting from a combination of insulin
resistance and inadequate insulin secretion (American Diabetes Association, 2015).  It is a life-
long, progressive condition and the presence of a diabetes diagnosis is associated with multiple
7complications and comorbidities as the disease progresses.  One of the common complications
resulting from progression of the disease is diabetic nephropathy.  Nephropathy occurs in 20% to
40% of patients with diabetes and is the leading cause of end-stage renal disease (ESRD)
(American Diabetes Association [ADA], 2015).  Another widely recognized classification for
nephropathy is diabetic kidney disease (DKD), which refers to a presumptive diagnosis of kidney
disease caused by diabetes (Ahmed, 2014).  The first clinical sign and early indicator of this
condition is the appearance of albumin in the urine in small amounts, defined as
microalbuminuria (Haller et. al, 2006).  Microalbuminuria is defined as urinary albumin
excretion of ≥ 30 mg/24 hours while albuminuria is defined as ≥ 300 mg/24 hours (The Diabetes
Control and Complications Trial [DCCT], 1993).  Important factors to consider in the
development of diabetic kidney disease (DKD) include hyperglycemia, duration of the disease,
hypertension, lipid abnormalities, albuminuria or proteinuria, ethnicity, genetic predisposition,
smoking status, and advancing age (Vivian & Mannebach, 2013).
Additionally, the presence of chronic kidney disease (CKD) along with diabetes
significantly increases a patient’s risk for cardiovascular disease.  CKD, particularly with the
presence of significant albuminuria, should be considered an additional cardiovascular risk factor
(Bakris et. al, 2010).  Therefore, the finding of microalbuminuria warrants screening for possible
vascular disease as well as aggressive interventions to reduce cardiovascular risk factors such as
lowering of LDL cholesterol, antihypertensive therapy, smoking cessation, and weight control
(ADA, 2004).  These interventions simultaneously decrease the progression of microalbuminuria
and decrease the patient’s risk for cardiovascular complications such as stroke or myocardial
infarction (MI).
8Significance for Advanced Practice Nurses
Fortunately, with early detection and intervention, the progression of renal disease and
risk for cardiovascular disease can be reduced dramatically.  The excess risk of death from any
cause in type 2 DM is associated almost entirely with the presence of kidney disease; in the
absence of diabetic kidney disease (DKD), the risk of death among persons with diabetes is
similar to that of the general population (Himmelfarb & Tuttle, 2013).  This illustrates the
importance of adequate monitoring for and early management of renal complications in the
diabetic patient.
DKD is primarily identified and monitored through assessments of kidney function
utilizing glomerular filtration rate (GFR) (<60 mL/min/1.73 m2) and kidney damage by
estimating albuminuria (>30 mg/g creatinine) (Tuttle et. al, 2014).  Without intervention, 20-40%
of type 2 DM patients with microalbuminuria progress to overt nephropathy (ADA, 2004).  With
proper intervention, progression to overt nephropathy can be prevented or progression slowed.
Although factors such as age and ethnicity cannot be controlled, others such as blood pressure
and lipid abnormalities can.  Adequate control of these modifiable risk factors can prevent renal
complications and enhance longevity and quality of life for type 2 DM patients.
Purpose
The aim of this review is to summarize the evidence available regarding identification
and treatment of microalbuminuria to prevent progression to development of diabetes-related
kidney disease.  This review will summarize findings from several high quality randomized
controlled trials (RCTs) to determine which interventions have proven the most effective in
preventing renal complications among those with type 2 DM.
9Methods
In order to ensure a comprehensive view of the current literature regarding prevention of
renal consequences related to diabetes, several medical research databases were reviewed,
including the Cumulative Index to Nursing and Allied Health Literature (CINAHL), PubMed,
and EBSCOhost.  Search terms used included “diabetic nephropathy”, “microalbuminuria”, type
2 diabetes”, “renal complications”, “nephropathy”, and “diabetic kidney disease”.
The literature search was performed to identify current treatment strategies utilized in
diabetic patients who develop kidney disease as a complication.  Inclusion criteria included the
study being printed in the English language, published between 2005 and 2015, and including
patients with a dual diagnosis of type 2 DM and microalbuminuria.  A total of 10 studies meeting
this criteria were reviewed.
Results
The key factor in preventing DKD is monitoring for and identification of the presence of
microalbuminuria (ADA, 2015).  Multiple national guidelines have reached consensus that
screening for DKD should include measurement of urinary albumin excretion, serum creatinine,
and calculation of estimated glomerular filtration rate (eGFR) (Molitch et. al, 2004; International
Diabetes Federation, 2012; National Kidney Foundation, 2007).  The 2015 Standards of Care
recommend obtaining a quantitative urine albumin excretion level at the time of diagnosis of
type 2 DM and at least yearly thereafter (ADA, 2015).
Other important factors in prevention of diabetic nephropathy are control of HbA1c and
blood pressure control.  There are many agents useful in preventing the progression of DKD and
lowering the risk of cardiovascular events, including beta blockers, calcium channel blockers,
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diuretics, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin II receptor blockers
(ARBs).
Adequate glycemic control is an important factor in preventing the development of DKD.
There have been mixed results in determining whether or not intensive glucose control plays a
role in reducing the risk of developing microalbuminuria or overt diabetic nephropathy or
decreasing progression of existing impairment.  Several large-scale studies such as the DCCT
and the United Kingdom Prospective Diabetes Study (UKPDS) show that maintaining HbA1C
levels as close to 7% as safely possible prevents microvascular complications such as
microalbuminuria and macroalbuminuria (DCCT, 1993; UKPDS, 1998).  Many other RCTs and
systematic reviews suggest that intensive vs. conventional glucose control reduces the risk for
microalbuminuria and other renal complications associated with type 2 DM (Coca et. al, 2012;
Perkovic et. al, 2013; ACCORD, 2008).  Risk reduction rates achieved through intensive
glycemic control are estimated to be between 10% and 60% (Perkovic et. al, 2013; Skyler et. al,
2009).  However, tight glycemic control is not without risk, most notably the risk of severe
episodes of hypoglycemia (Slinin et. al, 2012; DCCT, 1993; ACCORD, 2008).  Many
organizations have come to the consensus that better outcomes are obtained with a goal HbA1c
level <7% but that lower levels should be attained on an individualized basis (ADA, 2014;
National Kidney Foundation, 2012).
Hypertension is recognized as a key contributing factor in the development and
progression of kidney disease in patients with type 2 diabetes (Thomas & Atkins, 2006).  Both
systolic and diastolic hypertension have been shown to accelerate the progression of nephropathy
(Vivian & Mannebach, 2013).  Therefore, aggressive treatment of hypertension is critical in
preventing the onset and progression of microalbuminuria and resultant DKD.  Recent guidelines
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suggest that diabetic patients should have a goal blood pressure of ≤130/80 mmHg (ADA, 2015).
ACE inhibitors and ARBs, which target the renin-angiotensin system, have been shown to have
more potent antiproteinuric effects with similar degrees of blood pressure detection compared
with other classes, and are therefore the preferred agents in patients with type 2 DM (Remuzzi,
Macia, & Ruggenenti, 2006;
Even in the absence of hypertension, it has been recommended that patients with type 2
diabetes be on either an ACE inhibitor or ARB to slow the progression of microalbuminuria.
Extensive literature exists regarding the benefits of such treatment (Strippoli et. al, 2006; Misra
& Stevermer, 2009; Juarez et. al, 2013; Yee, 2014).  Therefore, the ADA, American Association
of Clinical Endocrinologists (AACE), and the International Diabetes Foundation (IDF) all
endorse use of either an ACE inhibitor or an ARB in patients with type 2 DM, hypertension, and
micro- or macroalbuminuria (ADA, 2014; AACE, 2011; IDF, 2005).  Many studies have
explored whether or not an additional benefit can be attained by using an ACE inhibitor/ARB
combination.  The consensus is that combination therapy does not provide any additional
benefits and may even increase adverse events and therefore is not recommended (Fried et. al,
2013; Juarez et. al, 2013; Mann et. al, 2013; Vivian & Mannebach, 2013).
The National Kidney Foundation and ADA currently recommend using LDL-cholesterol
lowering medications such as statins to reduce the risk of major atherosclerotic events in patients
with type 2 DM and renal disease (National Kidney Foundation, 2012; ADA, 2015).  Targets
should be LDL cholesterol <100 mg/dL, triglycerides <150 mg/dL, and HDL cholesterol >40
mg/dL (ADA, 2014).  Higher levels of LDL cholesterol and triglycerides couple with low HDL
cholesterol appear to be associated with greater risks of albuminuria and declining GFR;
therefore, improvement in these parameters may play a role in reducing albuminuria (MacIsaac,
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Ekinci & Jerums, 2014).  Studies have shown that statins can play a role in reducing
microvascular complications of diabetes without a negative impact on renal outcomes (Colhoun
et. al, 2009; ACCORD, 2008; Haffner, 2003).
Conclusion
Many clinical trials intensifying the control of conventional risk factors have not shown
improved outcomes. However, interventions such as treatment with ACE inhibitors or ARBs,
lowering LDL cholesterol, and optimizing blood pressure control have proven somewhat
effective in treating and preventing the progression of diabetic kidney disease.  With the
decreases in length and quality of life and health costs related to this complication, it is vital to
continue to explore safe and effective management strategies. Many of the interventions
identified in reducing the risk for diabetic nephropathy relate directly to controlling the
modifiable risk factors.
The most important consideration in preventing renal complications associated with type
2 DM is the monitoring for and early identification of microalbuminuria to prevent the
progression to DKD.  Once identified, renoprotective and cardioprotective measures can be
initiated to prevent the progression and delay complications.
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Table 1: Summary of Articles Assessed in Literature Review
Interventions to Decrease Diabetic Kidney Disease and Associated Increase in CVD risk
Citation Design Sample Purpose Findings Implications
Coca et. al,
2012
Systematic
review
7 RCTs
involving
28,065 adults
monitored
between 2 to 15
years
To
summarize
the benefits
of intensive
vs.
conventional
glucose
control on
kidney-
related
outcomes for
adults with
type 2 DM
Intensive glycemic
control reduced
the risk for
microalbuminuria
and
macroalbuminuria,
but not doubling
of the serum
creatinine level or
death from renal
disease compared
with conventional
control
Intensive glucose control reduces the risk for
microalbuminuria and macroalbuminuria, but
evidence is lacking that it reduces the risk for
significant clinical renal outcomes such as
doubling of the serum creatinine level, ESRD,
or death from renal disease.
Colhoun et.
al, 2009
Randomized
placebo-
controlled
trial
2,838 patients
with type 2
diabetes and no
previous CVD
To examine
whether
atorvastatin
affects
diabetic
kidney
disease and
whether the
effect of
atorvastatin
on CVD
varies by
kidney status
in patients
Atorvastatin
treatment was
associated with a
modest
improvement in
annual change in
GFR that was
most apparent in
those with
albuminuria
The data from this study provide reassurance
that the use of statins in the majority of
patients with diabetes delivers substantial
microvascular benefits, even in those with
modest impairment in kidney function, is safe
in regard to renal outcomes, and may even
demonstrate a benefit on eGFR.
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with diabetes
Diabetes
Control and
Complications
Trial, 1993
Multi-center
RCT
1,441 patients To compare
conventional
with
intensive
diabetes
therapy with
regard to
their effects
on the
development
and
progression
of the early
vascular and
neurologic
complications
of IDDM.
Microalbuminuria
(urinary albumin
excretion of ≥ 40
mg/24 hours) or
albuminuria
(urinary albumin
excretion ≥ 300
mg/24 hrs)
developed in
fewer patients in
the intensive-
therapy group than
in the
conventional
therapy group.
Intensive therapy
decreased the
mean adjusted risk
of
microalbuminuria
from 43-56%
between the two
cohorts
Due to the demonstrated reduction in risks, it
is recommended that most patients with IDDM
be treated with closely monitored intensive
regimens with the goal of maintaining their
glycemic status as close to the normal range as
safely possible.  Intensive therapy should be
implemented with caution due to risk of
hypoglycemia.
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Fried et. al,
2013
(VA
NEPHRON-D
Study)
Multi-
center,
double-
blind,
randomized
controlled
study
1448 veterans
with diabetes
and estimated
GFR 30 to 89.9
mL/min/1.73m2
and a urinary
albumin-to-
creatinine ratio
of at least 300
To determine
the safety and
effect of
combining
ACE
inhibitor and
ARB therapy
in preventing
the
progression
of kidney
disease in the
presence of
proteinuria
Combination
therapy with an
ACE inhibitor and
an ARB was
associated with
increased risk of
adverse events
among patients
with diabetic
nephropathy
Due to the increased risk of adverse events,
this combination in patients with proteinuric
diabetic kidney disease does not provide an
overall clinical benefit
Juarez et. al,
2013
Randomized
controlled
trial (RCT)
133 patients
with type 2
diabetic
nephropathy
aged 58-74
To compare
the efficacy
of combining
the ACE
inhibitor
Lisinopril
and the ARB
irbesartan
with that of
each drug in
monotherapy
in slowing
the
progression
of type 2
diabetic
nephropathy
There were no
significant
differences in
proteinuria
reduction or blood
pressure control
between the 2
groups.  The
number of adverse
events such as
hyperkalemia was
the same between
all 3 groups.
Did not demonstrate a benefit of the
combination of Lisinopril/irbesartan compared
to either drug alone at optimal high doses or
Mann et. al,
2013
Randomized
controlled
9,628 patients
with diabetes,
To assess the
safety of the
SBP decreased
more with dual vs.
A combination of ACE inhibitors and ARBs
does not increase strokes or alter other major
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trial mean age of 66
years.  3,163 of
the participants
had
nephropathy
and 6,465 did
not
addition of an
ACE
inhibitor
(Ramipril) to
an ARB
(telmisartan)
versus
monotherapy
in light of a
recent study
suggesting an
increase in
stroke risk in
people with
diabetes and
renal disease
monotherapy and
the same number
of strokes
occurred between
the two groups.
Stroke rate was
higher in
participants with
than those without
diabetic
nephropathy, but
effects of dual
therapy vs.
monotherapy were
not different in
either subgroup
cardiovascular or renal events in patients with
diabetes, irrespective of the presence of
nephropathy
Perkovic et.
al, 2013
(ADVANCE)
RCT 11,140 total
participants;
5,571 in the
intensive group
and 5,569 in
the standard
treatment group
To study the
effect of
intensive
glucose
control on
major kidney
outcomes in
type 2
diabetes
Intensive glucose
control
significantly
reduced the risk of
ESRD by 65%,
microalbuminuria
by 9%, and
macroalbuminuria
by 30%.
Additionally, the
progression of
albuminuria was
significantly
reduced by 10%
and regression
significantly
increased by 15%.
Improved glucose control will improve major
kidney outcomes in patients with type 2
diabetes.
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Slinin et. al,
2012
Systematic
review
5 RCTs related
to intensive vs.
conventional
glycemic
control, 5
RCTs for lipid-
management
strategies, and
11 RCTs for
management of
albuminuria
To evaluate
data on the
glycemic,
lipid, and
albuminuria
management
in patients
with diabetes
and CKD
Intensive vs.
conventional
glycemic control
reduced the
development of
micro- and
macroalbuminuria
but did not reduce
the incidence of
primary or
secondary clinical
outcomes and was
associated with a
2.5-fold increase
in severe
hypoglycemia.
Statins did not
reduce all-cause
mortality or stroke
compared to
placebo in adults
with diabetes and
CKD.  Fenofibrate
increased
regression of
microalbuminuria
to
normoalbuminuria
compared to
placebo.
Intensive glycemic control and lipid
interventions did not improve clinical
outcomes in patients with type 2 DM.
Although interventions typically improved
albuminuria, evidence was insufficient to
determine whether treatment of albuminuria in
normotensive patients provides beneficial
effects on clinical outcomes. More intensive
management of patients with diabetes and
CKD has inherent risks, including severe
hypoglycemia, which should be considered
when formulating treatment strategies.
Strippoli et.
al, 2006
Systematic
review
49 studies
involving a
total of 12,067
To evaluate
the benefits
and harms of
The effects of
ACE inhibitors
and ARBs on
The role of ACE inhibitors in the management
of patients with DKD is well established.
There is RCT evidence that ARBs are not as
22
patients ACE
inhibitors and
ARBs in
patients with
DKD
renal outcomes
such as ESRD,
doubling of serum
creatinine,
prevention of
progression of
micro- to
macroalbuminuria,
and remission of
micro- to
normoalbuminuria
were similarly
beneficial
effective in preventing deaths in patients with
DKD as ACEIs.  Both agents prevent
progression of nephropathy and promote
regression to a more favorable clinical pattern
of normoalbuminuria.  Data suggest that the
cheaper class of agent with proven survival
benefit (ACEIs) should be used as first line
treatment.
Vivian &
Mannebach,
2013
Review Adult patients
≥ 18 years with
diabetic
nephropathy
To compare
the benefit of
additional
blockage of
the renin—
angiotensin—
aldosterone
system
through
combination
therapy with
an ACE
inhibitor and
ARB, or a
direct renin
inhibitor
(DRI), to
monotherapy
Combination
therapy with an
ACE inhibitor or
ARB, or DRI, has
not been found to
be more effective
than monotherapy
with either an
ACEI or ARB.
Furthermore, the
combination may
increase the risk of
hyperkalemia or
acute kidney
injury
Although ACE inhibitors and ARBs remain
first-line treatment for slowing the progression
of diabetic nephropathy, recent studies suggest
that combining the agents may increase
adverse events without any clinical benefit to
offset them
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Table 2: Healthy People 2020 Goal Related to Diabetic Kidney Disease
Goal Objective Baseline Rate Target Rate
D-12
To increase the
proportion of those
diagnosed with
diabetes who obtain
an annual urinary
microalbumin
measurement
33.6% 37%
(U.S. DHHS, 2013)
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Clinical Practice Guideline Analysis: Standards of Medical Care in Diabetes
Whitney R. Munroe
University of Kentucky
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Abstract
Purpose: To analyze the 2015 Standards of Medical Care in Diabetes published by the
American Diabetes Association (ADA), with a special emphasis on the sections related to
managing renal complications in patients with type 2 diabetes mellitus (DM).
Data Sources: American Diabetes Association (ADA) Standards of Medical Care in Diabetes,
literature review articles
Implications for Practice: There are a variety of screening and management measures that
should be taken in regard to all patients with type 2 DM.  Clinicians should take special care in
not only optimizing glucose control, but also in screening for and preventing complications such
as cardiovascular and renal disease.
Conclusion: The Standards of Medical Care in Diabetes offers providers guidelines for
providing high-quality, comprehensive care to patients with type 2 diabetes mellitus (DM).  It
includes management of the condition and prevention of complications, including interventions
and treatment specifically directed toward decreasing morbidity and mortality associated with
renal complications.
Keywords: Type 2 diabetes mellitus, management, guidelines, complications
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Clinical Practice Guideline Analysis: Standards of Medical Care in Diabetes
The clinical practice guideline reviewed for this analysis was Standards of Medical Care
in Diabetes developed by the American Diabetes Association (ADA).  The guideline was
originally developed in 1988 and was most recently updated in January 2015.
Scope and Purpose
Type 2 diabetes mellitus (DM) is defined as a state of hyperglycemia resulting from a
combination of insulin resistance and inadequate insulin secretion (ADA, 2015).  It is a life-long,
progressive condition and the presence of a diabetes diagnosis is associated with multiple
complications and comorbidities as the disease progresses.  For example, type 2 diabetes is the
leading cause of new cases of kidney failure, non-traumatic lower extremity amputations, and
blindness among adults (Schellenberg, Dryden, Vandermeer, Ha, & Korownyk, 2013; CDC,
2014; Ratner, 2012).  Furthermore, patients with diabetes have a two to four-fold greater risk for
heart disease and stroke than those without the disease (Ginsberg & MacCallum, 2009;
Unachukwu & Ofori, 2012; Stratmann & Tschoepe, 2011; Duan et. al, 2014).
Nationwide, type 2 diabetes has reached epidemic proportions.  In the United States, its
prevalence has more than tripled in the time period from 1980 to 2011; there are currently an
estimated 20.9 million people living in the country with this diagnosis and an additional 7
million still undiagnosed (CDC, 2011).  Additionally, it is projected that this rate will continue to
increase and by 2020 nearly half of all Americans will be affected (United Health Group, 2010;
CDC, 2012; Aston, 2013).  If the current predictions based on prevalence and incidence for Type
2 diabetes hold steady, more than 10% of the world’s population, or 552 million people, will
have the disease by 2030 (Hu, 2011; Hirsch et. al, 2012; International Diabetes Federation,
2013).  Financially this condition has an enormous impact on the health care system, costing an
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estimated $174 billion, with $116 billion accounting for direct costs and $58 billion for indirect
costs such as lost productivity, disability, and premature mortality (Sease, Franklin, & Gerrald,
2013; Dall et. al, 2014). As demonstrated above, type 2 DM has costs both financially and in
terms of quality of life of the patients affected.
Diabetes is the 6th leading cause of death in the state of Kentucky (Kentucky Diabetes
Report, 2013).  The 2010 Kentucky Behavioral Risk Factor Survey shows that as many as
370,000 adults in Kentucky have been diagnosed with diabetes and an additional 233,000 adults
have prediabetes (Kentucky Department for Public Health, 2010).  Rates vary from 3% of the
population in Oldham County to 16% in Casey County (Kentucky Institute of Medicine, 2007).
Costs in the state equaled $4.8 billion in 2011, with total hospitalization charges of $183 million
and $23 million for emergency department visits alone (Dickson, 2013).
Objective
The objective of the ‘Standards of Medical Care in Diabetes’ guideline developed by the
American Diabetes Association is to provide clinicians, patients, researchers, payers, and other
interested individuals with the components of diabetes care, general treatment goals, and tools to
evaluate the quality of care provided (ADA, 2015).  Since diabetes is such a complex condition,
this guideline provides some consistency in terms of treatment modalities, monitoring
recommendations, and management of complications resulting from progression of the disease.
Stakeholder Involvement
The professional group responsible for the development of the Standards of Medical
Care in Diabetes is the American Diabetes Association (ADA).  The professional practice
committee involved in the development of the Standards of Care is a multidisciplinary group
comprised of physicians, diabetes educators, registered dieticians, and others who have a wide
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range of expertise in areas such as adult and pediatric endocrinology, epidemiology, public
health, lipid research, hypertension, and preconception and pregnancy care (ADA, 2015).
Upon review of the member list of the professional practice committee, it appears that all
relevant groups were represented.  There were multiple physicians and a few advanced practice
nurses, a couple of whom specialized in diabetes.  This is important because these groups are
often directly involved in the diagnosis and management of patients with diabetes.  It is
important to have registered dieticians as part of the team because they are often involved in the
advanced dietary teaching and concepts such as carb counting that are so critical to the patient’s
self-management success.
The target users of the guideline are clearly identified as APRNs, allied health
professionals, dieticians, hospitals, nurses, patients, physician assistants, physicians, and public
health departments (ADA, 2015).  All of these groups are important to include due to direct
involvement and expertise in certain aspects of the management of type 2 diabetes.
Rigor of Development
The most recent revisions to the guideline were developed using a systematic review of
the Medline electronic database for current, relevant studies addressing each subsection that had
been published since January 1, 2014.  The first publication of the clinical practice guidelines
was in 1988 and each year the practice committee performs an extensive literature search and
updates the recommendations based on the quality of new evidence that has been released during
the previous year (ADA, 2015).  The recommendations are revised based on new evidence or, in
some cases, to clarify prior recommendations or match the strength of the wording to the strength
of the evidence.
The ADA developed a grading system in 2002 that is used to rate the strength of the
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evidence reviewed as either A, B, C, or E.  A grade of A is applied to well-conducted and
generalizable randomized controlled trials (RCTs); B to supportive evidence from well-
conducted case-control/cohort studies; C to supportive evidence from poorly or uncontrolled
studies, such as observational studies or RCTs with methodological flaws; and E to expert
consensus or clinical experience (ADA, 2015).  All levels of grading were represented in the
recommendation statements with special emphasis given to those with A or B ratings.
There appears to be a strong link between the recommendations and supporting evidence.
For example, the ADA and the European Association for the Study of Diabetes (EASD) formed
a joint task force to evaluate data and develop recommendations for use of anti-hyperglycemic
agents in type 2 diabetic patients (ADA, 2015).  This statement reaffirms the use of metformin as
a first line agent due to a long-standing evidence base surrounding its efficacy, safety, and
potential for reducing the risk of cardiovascular events (Holman, Paul, Bethel, Matthews, & Neil,
2008).  Many of the recommendations have strong correlating evidence to support their utility in
clinical practice, either for direct treatment or risk reduction.
The method used to formulate the recommendations was expert consensus.  The
recommendations were reviewed and approved by the Executive Committee of ADA’s Board of
Directors, which includes health care professionals, scientists, and lay people (ADA, 2015).
They also underwent internal review by the professional practice committee and consensus was
reached between the two groups before publication of the recommendations.
Clarity and Presentation
The recommendations provided are very specific.  There are a total of 14 subsections,
with more specific recommendations under each heading that are directly related to the topic
presented.  The lab values needed for diagnosis are very precise, as well as the conditions under
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which they need to be obtained.  There is an easy to follow algorithm for initiating drug therapy
for hyperglycemia that can be individualized for many circumstances such as for elderly patients,
cost minimization, prevention of hypoglycemia, etc.  The recommendations are also clear that
unless contraindications exist, metformin should be the initial therapy for all diabetic patients
(ADA, 2015).  Concrete values are provided for different areas of management, such as 150
minutes/week for physical activity and parameters to track such as HbA1c, microalbuminuria,
and blood pressure and cholesterol targets for risk reduction.  There is also a section dedicated to
changes made in comparison to the prior year’s recommendations, which allows clinicians
already familiar with many of the recommendations to focus exclusively on what has changed.
One important area of focus is the section on screening for and diagnosis of type 2
diabetes because it serves as a basis for the remainder of the recommendations.  The Standards
of Care recommendations are very specific in stating that diagnosis must be made with a fasting
plasma glucose level, a 2 hour oral glucose tolerance test, or the recently added option of HbA1c
level ≥ 6.5% (International Expert Committee, 2009).  Additionally, the screening
recommendations include all individuals 45 years of age or older as well as those identified at
increased risk (i.e. first degree relative with diabetes, hypertension, women with PCOS, BMI ≥
25, individuals identified as being prediabetic) (ADA, 2015).  Once a patient is identified as
having the condition, the remainder of the practice recommendations may be utilized.
The key recommendations of this guideline are numerous.  However, the standards of
care are divided into 14 specific areas of recommendations as follows:
 Strategies for Improving Care
 Classification and Diagnosis of Diabetes
 Initial Evaluation and Diabetes Management Planning
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 Foundations of Care: Education, Nutrition, Physical Activity, Smoking Cessation,
Psychosocial Care, and Immunization
 Prevention or Delay of Type 2 Diabetes
 Glycemic Targets
 Approaches to Glycemic Treatment
 Cardiovascular Disease and Risk Management
 Microvascular Complications and Foot Care
 Older Adults
 Children and Adolescents
 Management of Diabetes in Pregnancy
 Diabetes Care in the Hospital, Nursing Home, and Skilled Nursing Facility
 Diabetes Advocacy
More targeted recommendations are provided under each subsection as relevant to that
content area.  These subsections are designed to facilitate access to information of interest in a
timelier manner by providing it in a logical and relevant manner.
There are a total of 207 recommendations within this guideline.  The key
recommendations are easily identifiable in the ‘Executive summary’ section of the document,
with the subsections in bold text and capital letters and the relevant key recommendations
bulleted underneath.  The full text of the guideline offers more detailed explanations for each of
the specific recommendations, including a summary of the evidence surrounding them.  The
recommendations can be easily located within purple boxes in each relevant section.
Guideline Application
Organizational barriers in applying the recommendations include time involved for direct
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patient care, reimbursement rates, and resources available in terms of electronic systems and
multidisciplinary team members. For example, various patient insurance coverage levels may
serve to hinder the utility of some of the recommendations surrounding oral agents.  If a
particular medication is not covered, it is unlikely that the patient will follow the treatment plan.
Staffing and changes in workflow required to meet the high educational demands of a newly
diagnosed diabetic patient may not meet the level set forth in the recommendations.
Additionally, in rural settings access may be limited to specialized providers such as
endocrinologists and ophthalmologists specializing in diabetic care and prevention of
complications.  These barriers were not explicitly stated in the text of the Standards of Care
document.
The document containing the recommendations set forth by the ADA is very lengthy and
therefore is not ideal for timely use in the practice setting.  However, many abbreviated
documents such as the executive summary and clinical algorithms have been developed to make
the recommendations more user-friendly and applicable.  Additionally, the document is divided
into sections, making it easier for a clinician to access content relevant to current needs.
It is explicitly stated that a formal cost analysis was not performed nor were published
cost analyses reviewed during the development of this guideline (ADA, 2015).  However, it was
stated that most of the interventions recommended have been shown to be cost effective.
Furthermore, it is inherent that early recognition and prevention of complications common with
diabetes will help decrease long term costs.
Theoretical Framework
Type 2 diabetes management is quite complex, and the use of such evidence based
clinical practice guidelines as the Standards of Medical Care in Diabetes can help enhance the
33
ability of health care practitioners to effectively address all the needs of these patients.  Since
revisions are made to the recommendations annually, it is important for practicing clinicians to
keep up to date on the changes and implement them into the clinical setting.  A theoretical
framework that could be used to enhance this process is the diffusion of innovations theory.
Developed by E.M. Rogers in 1962, this theory consists of four distinct stages of
adoption: the knowledge phase, the persuasion stage, the decision stage, and the final stage
(Moulding, Silagy, & Weller, 1999).  Knowledge and attitude change alone are thought to lead to
changes in practice.  Each year when the new revision is released, the information has to be
disseminated to clinicians, which represents the knowledge phase.  This involves the publication
of the revisions on the ADA website, in-services about the changes, etc.  The persuasion stage
involves the attitude, either positive or negative, about the new recommendations. In this stage,
people want to know the advantages and disadvantages of the recommendations and how these
will influence them.  The decision stage tests whether or not individuals and groups find the
recommendations acceptable, and the final stage leads to the actual adoption or rejection of the
guideline into practice (Moulding, Silagy, & Weller, 1999).  During the process, these steps
address any gaps in practitioner knowledge about the guideline, which allows more effective
implementation into practice.
Editorial Independence
This guideline was developed and funded by the American Diabetes Association (ADA).
The development of the standards is funded by the organization and no outside support is used.
The Standards of Care are based on scientific evidence, but this annual document also serves as
the position statement for the ADA, and the statements in this section represent official ADA
opinions on selected topics not adequately covered elsewhere (ADA, 2015).  There is a
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disclosure stating that all members of the professional practice committee were required to
disclose potential conflicts of interest with industry, and there is a table on page S88-S89 of the
manuscript listing all individuals and their financial or other potential conflicts of interest during
the 12 months leading up to the publication date.
Recommendation
While the Standards of Care is likely the most highly recognized diabetes management
guideline in the United States, there are similar guidelines published by other organizations
pertaining to type 2 diabetes recognition and treatment that are also useful in clinical practice.
These organizations include the American Association of Clinical Endocrinologists (AACE) and
the International Diabetes Federation (IDF). Both of these guidelines also focus on diagnosis and
comprehensive evaluation and management of diabetic patients.
The AACE ‘Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus
Comprehensive Care Plan’ share many of the recommendations as those put forth by the ADA.
The diagnostic parameters are identical, and both guidelines share the recommendations for
medical nutrition therapy and highlight the importance of concomitant therapeutic lifestyle
changes such as diet and exercise.  However, the AACE’s recommendations for oral therapy are
not as specific, and metformin is not singled out as the preferred first-line therapy (Handelsman
et al., 2011).  The AACE has developed a set of ten algorithms to make the application of the
recommendations simple to apply in a time-saving manner.
The IDF ‘Global Guideline for Type 2 Diabetes’ also addresses many of the same areas
of management for patients diagnosed with diabetes.  Both the IDF and ADA guidelines agree on
a target HbA1C level of ≤ 7%, while the AACE guideline leaves this area more open to
interpretation by stating that these targets should be individualized based on age, comorbidities,
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and duration of disease (Handelsman et al., 2011) rather than specifying a value.  Since the IDF
guideline was developed by a worldwide panel of organizations, the recommendations set forth
encompass a broader view of diabetes management globally (IDF Clinical Guidelines Task
Force, 2010).
All of the aforementioned guidelines emphasize the importance of optimization of blood
glucose levels in order to prevent complications and assist practitioners in navigating the
complex management of type 2 diabetes.  All three are useful adjuncts to practice and address
many important care issues such as appropriate monitoring, timeframes, and follow-up to assist
in organizing appropriate management strategies and ensuring that all patients receive the highest
quality of care possible.
The National Kidney Foundation (NKF) has also developed a guideline specifically
relating to the screening for and diagnosis of diabetic kidney disease.  Like the ADA guideline,
this guideline also recommends screening for microalbuminuria at the time of diagnosis of type 2
DM and annually thereafter (National Kidney Foundation, 2007).  Additionally, the
recommendations are also the same in terms of initiating treatment with an ACE inhibitor or
ARB if microalbuminuria is present.  Recommendations differ in that the NKF guideline
specifically recommends that urine be collected utilizing first morning urine or overnight
collection, while the ADA guideline does not.  Also, the NKF guideline advises that 2 to 3
samples should be positive for micro- or macroalbuminuria before classification is determined.
Since this guideline relates specifically to diabetes-associated kidney disease, it is more
comprehensive in this specific area than the ADA’s Standards of Care.
Application in Practice
The ADA Standards of Care have a long-standing reputation for recommending quality
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evidence-based strategies for type 2 diabetes management that are relevant to the current
evidence.  It holistically addresses all aspects of care and provides clinical algorithms for
application in the clinical setting.  The fact that this guideline is revisited and updated annually is
a benefit because it increases the likelihood that the latest scientific evidence is translated into
practice sooner.  This guideline is particularly useful in the primary care setting because it is
applicable to patients in all age ranges and also addresses special populations such as pregnant
patients and those in institutionalized settings.  Since type 2 diabetes affects each individual
differently, it is not rigid and allows flexibility and individualization based on patient needs.  For
these reasons, it can be very useful in guiding the actions of health care practitioners in the high
quality management of this chronic condition.
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Table 3. ADA Recommendations Regarding Diabetic Nephropathy
 Optimize glucose control to reduce the risk or slow the progression of DKD
Strength of Recommendation: A
 Optimize blood pressure control to reduce or slow the progression of DKD
Strength of Recommendation: A
Screening
 At least once per year, quantitatively assess urine albumin (utilizing urine albumin-to-
creatinine-ratio [UACR] and estimated GFR ) in patients with type 1 diabetes with a
duration of ≥ 5 years and in all patients with type 2 diabetes
Strength of Recommendation: B
Treatment
 An ACE inhibitor or ARB is not recommended for primary prevention of DKD in
patients who are normotensive and have a normal UACR (<30 mg/g)
Strength of Recommendation: B
 Either an ACE inhibitor or ARB is suggested for the treatment of the non-pregnant
patient with modestly elevated urinary albumin excretion (30-299 mg/day) and is
recommended for those with levels >300 mg/day
Strength of Recommendation: A
 Serum creatinine and potassium levels should be monitored when ACE inhibitors, ARBs,
or diuretics are used to assess for increased creatinine or changes in potassium
Strength of Recommendation: E
 Continued monitoring of UACR is reasonable for patients with albuminuria to monitor
progression of the condition
Strength of Recommendation: E
 Evaluate and manage potential complications of CKD when GFR is <60 mL/min/1.73m2
Strength of Recommendation: E
 Consider referral to a renal specialist when there is uncertainty about the etiology of
kidney disease, management issues, or advanced kidney disease
Strength of Recommendation: B
Nutrition
 For patients with DKD, reducing protein intake below the recommended daily intake of
0.8g/kg/day is not recommended because it does not alter glycemic measures, CV risk
measures, or the course of GFR decline
Strength of Recommendation: A
Note: Table adapted from ADA’s 2015 Standards of Medical Care in Diabetes (ADA, 2015)
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Abstract
Purpose: The purpose of this study was to evaluate provider adherence to the ADA’s
recommendation for an annual screening urinary albumin excretion level to check for the
presence of microalbuminuria.  A secondary objective was to assess for adequate treatment (i.e.
ACE inhibitor or ARB prescription) in those patients with microalbuminuria present.
Methods: A retrospective chart review was conducted on 60 randomly selected patients seen
within a primary care practice in an urban university setting between January 1st, 2014 and
December 31st, 2014.  Inclusion criteria included age ≥ 18 years and an active diagnosis of type 2
DM as evidenced by ICD codes 250.00-250.93.  Data collected included age, gender, ethnicity,
marital status, insurance type, BMI, tobacco use status, presence or absence of a urinary albumin
excretion level collected within the specified timeframe, and presence or absence of an active
ACE inhibitor/ARB prescription.  A database of 972 qualifying patients was provided by the
university’s Division of Biomedical Informatics and 60 patients were randomly sampled from
this database utilizing a random number generator.
Results: The retrospective chart review demonstrated only 1 out of the 60 charts reviewed had
received screening for microalbuminuria within the previous calendar year, as recommended by
the national guidelines.
Conclusion: Increasing urinary albumin excretion rate screening is essential in early recognition
and management of renal complications in patients with type 2 DM.  Current rates in many
practice settings appear to be suboptimal and there exists an opportunity for quality improvement
and identifying strategies for improving screening rates.
Keywords: microalbuminuria, type 2 diabetes, diabetic kidney disease, diabetic nephropathy
44
Assessment of Screening Practices for Diabetic Kidney Disease in a Primary Care Setting: A
Retrospective Chart Review
Type 2 diabetes mellitus (DM) is a complex condition, affecting nearly all organ systems
in the body.  As a result, management focuses not only on optimizing glucose control, but also
on decreasing micro- and macrovascular complications.  One of the most common microvascular
complications resulting from type 2 DM is the development of diabetic nephropathy, which over
time can progress to end stage renal disease (ESRD).
Currently, 10 to 40 percent of all patients with a diagnosis of type 2 DM will eventually
develop diabetic nephropathy, which is the leading cause of ESRD in the United States (Lepore,
Maglio, & LeRouth, 2008; Ganesh & Lee, 2011; National Kidney Foundation, 2015).
Approximately 40 percent of all new cases of ESRD in the United States each year occur in
patients with diabetes (American Diabetes Association [ADA], 2007).  This is a result of a direct
insult to the small vessels of the renal system that develops over time.  In addition to leading to
the need for dialysis and/or renal transplantation and decreasing overall quality of life, the costs
associated with treatment of patients with type 2 diabetes with ESRD exceeds $15.6 billion
(United States Renal Data System, 2012).
In Kentucky, renal complications from diabetes comprise a small percentage of
hospitalizations at only 2.4%.  However, these hospitalizations rank 2nd in the longest average
length of stay at 6.88 days, have the highest average charge of $58,830 per patient, and represent
the highest billed charges in 2013 at $24,179,328 (Kentucky Diabetes Report, 2015).  Therefore,
reductions in renal complications related to type 2 DM could result in significant healthcare cost
savings throughout the state.
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One of the most important factors in delaying the development of diabetic kidney disease
and progression to ESRD is early identification.  This is accomplished through the annual
screening for microalbuminuria recommended by the American Diabetes Association (ADA),
beginning at the time of diagnosis for all patients with type 2 DM (ADA, 2015).
Background
Although diabetic nephropathy occurs in patients with type 1 DM as well, it occurs
earlier and in higher proportions in patients with type 2 DM due to presence of the disease for
longer periods prior to diagnosis (ADA, 2004). There is also a higher proportion of patients with
type 2 DM who also have a diagnosis of hypertension, which further increases the change of
microalbuminuria and resultant renal disease.
Presence of microalbuminuria in the urine is not only the earliest clinical marker for
diabetic nephropathy, but it also signifies an increased risk of cardiovascular morbidity and
mortality (Weir, 2007; Adachi, 2014).  Therefore, its presence should also alert clinicians to
intensify interventions to reduce cardiovascular risk factors and to screen for cardiovascular
disease.
Healthy People 2020 identified a goal specific to management of renal complications
associated with type 2 DM, which is to increase the proportion of Medicare patients with an
annual urinary albumin excretion measurement to at least 37 percent (United States Department
of Health and Human Services [DHHS], 2013).  This would reflect an increase of 10 percent in
the current screening rate of only 33.7%. Since 2007, data has been monitored annually; there
has been an increase in screening rates each year, and in 2011 the screening rate was at 40.8
percent.  Therefore, this goal should be achieved if current practices remain consistent.
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The ADA Standards of Medical Care in Diabetes guideline provides clinicians with
specific guidance on screening for and management of microalbuminuria in patients with
diabetes. One of the recommendations of this guideline pertains to obtaining an annual urinary
albumin excretion level in patients with type 2 DM beginning at the time of diagnosis and
treatment of patients with microalbuminuria with either an angiotensin-converting enzyme
(ACE) inhibitor or angiotensin II receptor blocker (ARB) (ADA, 2015).
Timed 24-hour urine collections are considered the gold standard in screening for the
presence of albuminuria.  However, the use of these tests in the primary care practice setting can
be impractical due to factors such as improper collection by patients, inconvenience, and cost.
As a result, many studies have identified a spot albumin-to-creatinine ratio (ACR) as an
acceptable and cost-effective screening method in the primary care setting (Lepore et. al, 2002;
Younes et. al, 2010; Wu et. al, 2014; Teo et. al, 2015). While first morning void is preferred as
albumin levels can fluctuate throughout the day, these studies found urine collection at the time
of appointment to be sufficient as long as a repeat test was performed to confirm elevated levels.
Microalbuminuria is present if the result is ≥ 30 mg/g creatinine.
Purpose
The purpose of this study was to evaluate provider adherence to the American Diabetes
Association’s (ADA) recommendation to obtain an annual urinary albumin excretion level for
the early identification of renal complications associated with type 2 DM.  A secondary aim was
to assess adequate treatment in those identified as higher risk, as evidenced by urinary albumin
excretion levels ≥ 30 mg/g creatinine.
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Methods
Design
A retrospective review of 60 medical records of patients with type 2 DM was performed
in March 2015 to assess for the presence or absence of a urinary albumin excretion level
collected within the previous calendar year as evidenced by documentation in the electronic
health record (EHR).  If a level was obtained and found to be elevated, assessment for whether or
not an intervention was made (i.e. prescription for an ACE-I or ARB) was also performed.
Human Subject and Research Approval Procedures
After obtaining committee approval for the project, permission to conduct the study was
sought and obtained from the university’s institutional review board (IRB).  A waiver of
informed consent was obtained as the data collected was retrospective in nature and de-identified
prior to receipt by the primary investigator.  As such, there was minimal risk to participants
involved in the study.  A permission letter allowing the primary investigator to access the
electronic health record (EHR) was obtained from the practice prior to data collection.  Proper
documentation and training was completed through the Division of Biomedical Informatics prior
to data release.
Data Extraction and Study Population
This study was conducted at a primary care clinic within a university setting.  This clinic
employs two full-time physicians and two nurse practitioners.  The patient population ranges
from newborn to elderly and includes a wide range of services and management of both acute
and chronic conditions, including diabetes.  A list of 972 patients from this clinic meeting
inclusion criteria was extracted by the Division of Biomedical Informatics within the Center for
Clinical and Translational Science at this university.  Inclusion criteria included having been
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seen in the clinic between the dates of January 1st, 2014 to December 31st, 2014; age ≥ 18 years,
and an active diagnosis of type 2 DM as evidenced by an ICD code of 250.00-250.93.  All data
was de-identified prior to receipt.  From this list, the primary investigator narrowed the sample to
60 charts using systematic sampling utilizing a random number generator.  All data collected was
entered into a Microsoft Excel spreadsheet and stored in REDCap®, which is a secure, password
protected web-based application utilized by the university (Harris et. al, 2009).
Data Analysis
Data analysis was performed using the SPSS statistical software package.  Demographic
data collected included gender, age, ethnicity, insurance type, presence or absence of a urinary
albumin excretion level obtained between January 1st, 2014 to December 31st, 2014, and
presence of a prescription for treatment medications (ACE inhibitor or ARB), if applicable.
These measures were assessed using descriptive statistics including frequencies, percentages,
standard deviations, and means.
Results
Of the 60 patient charts selected for review, 23 (38.3%) were male and 37 (61.7%) were
female.  Ages ranged from 22.32 to 95.17 years for a mean of 53.86 years (SD=15.6). Forty-
eight and 3/10 percent of the subjects (29/60) were Caucasian, while 45 percent (27/60) were
African American, 3.3 percent (2/60) were Hispanic, 1.7% (1/60) Asian, and the ethnicity of one
subject was unreported.  Mean body mass index (BMI) of this sample was 33.7 (SD=9.6),
although this is likely skewed since over half of the charts reviewed had no recorded BMI. Fifty
percent (30/60) of the patients whose charts were reviewed were identified as current tobacco
users, which is significant since smoking has been identified as an independent risk factor for
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microalbuminuria and faster progression of DKD (Cederholm et. al, 2005; Voulgari,
Katsilambros, & Tentolouris, 2011)
Only one of the 60 charts reviewed had a documented urinary albumin excretion level
charted within the preceding calendar year for a rate of 1.7%.  This patient had microalbuminuria
present but did not have an active prescription for an ACE inhibitor or ARB as recommended per
the guidelines.  Of the 60 patients whose charts were reviewed, 19 (31.7%) were prescribed an
ACE inhibitor and two (3.3%) were prescribed an ARB, although indication for these
medications is unclear.  Although specific indications are not known (i.e. prescribed for elevated
blood pressure, microalbuminuria, etc.), blood pressure control may also be important for
prevention of renal issues.
An incidental finding of this chart review is that many of the patients whose charts were
reviewed had no body mass index (BMI) recorded, which is important clinical data, especially
for patients with diabetes.  Of the 60 charts reviewed, 35 (58.3%) were missing this information.
This is significant to this study since some studies have shown an association between BMI and
the presence of microalbuminuria and risk for developing diabetic nephropathy (Kramer et. al,
2009; Pavan et. al, 2011; Svensson et. al, 2015).
Recommendation
Based on the findings from this retrospective chart review, it is recommended that this
facility institute quality improvement measures to increase their screening for microalbuminuria
among the patient population diagnosed with type 2 DM.  Once quality improvement measures
have been identified and implemented, follow-up should be performed to determine if any
significant improvements have been made.
50
Discussion
The screening for and early identification of microalbuminuria in patients with type 2
DM is essential in the prevention or delay of diabetic nephropathy.  Appropriate interventions
will hopefully increase patient quality of life by slowing progression to ESRD and the possible
need for dialysis or renal transplant.  It will also decrease costs associated with these
complications.  The ADA’s Standards of Care, the National Kidney Foundation’s KDOQI, and
the American Association of Clinical Endocrinologist (AACE) guidelines are all concurrent on
the recommendation that this screening be performed annually, beginning at the time of
diagnosis.
Despite a national emphasis on the early detection of renal complications associated with
type 2 DM, minimal information is known about actual screening practices in the primary
practice setting.  Few published studies are available that have measured screening rates, and
very few recent studies were located.  Studies in the literature have shown screening rates for
microalbuminuria to be between 12%-49% (Kraft et. al, 1999; Weiner et. al, 1995; Kirkman et.
al, 2002; Gill et. al, 2006; Hellemons et. al, 2012; Anabtawi & Mathew, 2013).  Although
screening rates from this chart review were expected to be suboptimal, actual results were much
lower than expected.  As stated above, only one of the 60 patients in the randomly selected
sample had a urinary albumin excretion rate performed within the previous year.  Even when
considering all patients in the initial database, only 39 out of 972 had the appropriate screening
for a rate of 4%.  This is not to say it is representative of the clinic as a whole or that these
patients had never been screened for microalbuminuria, but it definitely signifies an opportunity
for improvement in meeting the recommendations of annual screening in all patients with type 2
DM.
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Limitations
A major limitation in this study was the small size and homogeneity of the sample.  Since
only a small population from one clinic was studied generalizability to a larger population is
unclear.
Also, it appears that enough clinical data was not obtained to allow any significant
associations to be shown.  Since only one chart had a urinary albumin excretion level present
within the preceding calendar year, no relationships between screening rates and patient
characteristics could be inferred.  Additionally, no indications were provided for ACE inhibitor
or ARB therapy so it was not possible to conclude whether they were being used for
microalbuminuria specifically or for another use such as hypertension.
Finally, this study did not assess for the presence of regular screening of estimated
glomerular filtration rate (eGFR).  The ADA clinical practice guideline recommends the annual
screening of both urinary albumin excretion levels and eGFR.  While similar studies also had not
assessed for this level and it takes longer for the eGFR to be affected than for microalbuminuria
to appear, it could have increased confidence that renal function was being evaluated in some
capacity.
Implications for Practice
Existing literature as well as data from the Healthy People 2020 illustrates that despite
guideline recommendations, screening for urine microalbuminuria remains low (U.S. DHHS,
2013).  This retrospective chart review likewise demonstrates suboptimal screening practices and
an opportunity for quality improvement in this area.
Future research should be directed towards barriers that prevent clinicians from obtaining
an annual urinary albumin excretion level as recommended by guidelines.  Useful strategies
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possibly include use of a tool such as the Diabetes Care Tool provided by the Kentucky Diabetes
Network or a reminder prompt integrated into the clinic’s electronic health record (EHR).
Additional strategies may include a provider focus group to identify potential barriers or an
educational session to raise clinicians’ awareness of the ADA’s recommendations.  The
effectiveness of these interventions could be tested utilizing a pre- and post-intervention design.
Conclusion
Type 2 DM affects almost every organ system in the body, including the renal system.
Significant progress needs to be made in the clinical setting to reach the goal set forth by Healthy
People 2020 to increase annual urine microalbumin measurements to at least 37% (U.S. DHHS,
20l3). This chart review showing low levels of adherence is consistent with findings from other
studies. Because screening for microalbuminuria and initiation of proper treatment can delay the
progression to overt nephropathy, this should be considered essential in the care of every patient
diagnosed with type 2 DM.
Additional research is needed to determine whether suboptimal screening rates are due to
factors such as lack of time, lack of knowledge, lack of organizational support/resources, or other
factors.  One this is identified, interventions for improving screening rates can be tailored to
target the identified reasons.
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Table 4. Characteristics of Patient Sample from Retrospective Chart Review
N %
Gender
Male
Female
23
37
38.3
61.7
Ethnicity
Caucasian
African American
Hispanic
Asian
Unknown
29
27
2
1
1
48.3
45
3.3
1.7
1.7
Insurance Type
Medicaid
Medicare Part A
Medicare Part B
Commercial Insurance
Self Pay
Clinical Research
18
7
9
9
5
2
30
11.7
15
15
8.3
3.3
Mean SD
Age 53.6 15.6
BMI 33.7 9.6
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Figure 1. Guideline Adherence Rates from Retrospective Chart Review
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Care of the diabetic patient is complex, and certain aspects of care sometimes get
neglected in the patient care setting.  As suggested through literature review, Healthy People
2020 data, and this pilot chart review, annual screening for urinary albumin excretion is likely
one of these dimensions that is often overlooked.  Whether this is due to lack of time, lack of
knowledge, lack of organizational support, etc., further research should be conducted to explore
options for increasing the overall screening rates. Most patients with type 2 DM are seen in the
clinic every 3 to 6 months, so as long as clinicians identify that screening needs to occur, there is
ample opportunity to do so.
By improving screening, primary care providers are helping provide high-quality,
comprehensive care to all patients while also decreasing morbidity and mortality and associated
health care costs. This step is imperative because it is what leads the clinician to identify a
potential problem and initiate appropriate treatment to prevent further complications.
The screening rate at the clinic utilized for this study were much lower even than
suggested by the literature.  Therefore, recommendations include identifying barriers to
obtaining UACR levels in this setting, as well as instituting quality improvement strategies to
ensure that it is being performed.  Once these measures have been implemented, a repeat chart
review should be performed to assess for improvement.
Further research should also be conducted regarding specific strategies that may improve
screening rates, such as the use of prompts integrated into a facility’s EHR or a tool such as the
Diabetes Care Tool supplied by the Kentucky Diabetes Network.  Organizational support and
emphasizing the need for improvement in this area to providers can assist in meeting the
nationwide goal set forth by Healthy People 2020 for improving the overall screening rates to at
least 37%.
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